En la Revisión de J. Latour-Pérez (Med. Intensiva 2001; 25: 229-235), en el apartado correspondiente a resultados y conclusiones del resumen en inglés, donde dice: “AGIIb/IIIa administration improves patients’ expectation of survival when there is high risk of death/infarct, low risk of hemorrhage and normal preferences”, debe decir: “AGIIb/IIIa administration improves patients’ expectatives when there is high risk of death/infarct, low risk of hemorrhage and normal preferences.